Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 12/20 | 0.34 |
| ▸ | FEN1 | P39748 | 11/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.34 |
| ▸ | PTGFR | P43088 | 2/20 | 0.34 |
| ▸ | PTGIR | P43119 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | SDCBP | O00560 | 1/20 | 0.31 |
| ▸ | SDC2 | P34741 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129120 | 0.80 | F10 (0.48) | F10 | |
| SCHEMBL7130064 | 0.75 | ALOX5AP (0.38) | ALOX5APFEN1PTGER1PTGER3PTGER4 | |
| SCHEMBL7121933 | 0.71 | HPGD (0.44) | ALOX5APFEN1F10 | |
| SCHEMBL7129110 | 0.69 | F10 (0.59) | ALOX5APFEN1F10 | |
| SCHEMBL7125640 | 0.69 | LMNA (0.51) | ALOX5APFEN1SDCBPSDC2 | |
| SCHEMBL7117836 | 0.67 | ALOX5AP (0.51) | ALOX5APFEN1PTGER1PTGER3PTGER4 | |
| SCHEMBL7122641 | 0.67 | GAA (0.43) | SDCBPSDC2 | |
| SCHEMBL7118364 | 0.64 | RAB9A (0.47) | ALOX5APFEN1F10 | |
| SCHEMBL7126469 | 0.64 | KDM4E (0.56) | ALOX5APFEN1 | |
| SCHEMBL7128783 | 0.62 | ALOX5AP (0.47) | ALOX5APFEN1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002096873-A1 | ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | SERPINC1, F11, TFPI | ALOX5AP 415/4885FEN1 1574/4885PTGER1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.